title: Chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancer.
abstract: Thirty-three evaluable patients with metastatic breast cancer (12 previously treated with adjuvant chemotherapy) were treated with a combination of cis-platin, doxorubicin, and cyclophosphamide (CAP). cis-Platin was given intravenously, 20 mg/m2, on days 1-3, doxorubicin, 40 mg/m2 i.v., on day 1, and cyclophosphamide, 200 mg/m2 i.v., on days 1-3. Cycles were repeated every 3 weeks. A complete response (CR) was obtained in 3 patients (9%) and a partial response (PR) in 18 (54%). The highest response rate was observed in soft tissue and in liver metastases. Median response duration was 48 weeks and median survival 93 weeks. Toxicity was moderate and consisted of alopecia (100%), gastrointestinal toxicity (86%), and myelosuppression (60%). We conclude that this regimen is active in the treatment of advanced breast carcinoma, with a generally acceptable tolerance, but further evaluations in Phase III studies are required.
authors.affiliation: Division of Medical Oncology, Ospedale Policlinico, Perugia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Colozza
authors.forename: S
authors.initials: S
authors.lastname: Gori
authors.forename: A M
authors.initials: AM
authors.lastname: Mosconi
authors.forename: V
authors.initials: V
authors.lastname: Belsanti
authors.forename: C
authors.initials: C
authors.lastname: Basurto
authors.forename: R
authors.initials: R
authors.lastname: Rossetti
authors.forename: F
authors.initials: F
authors.lastname: Di Costanzo
authors.forename: F
authors.initials: F
authors.lastname: Buzzi
authors.forename: M
authors.initials: M
authors.lastname: Bacchi
authors.forename: S
authors.initials: S
authors.lastname: Davis
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D012074:Remission Induction
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin